Radius Health, Inc. (RDUS) News
Filter RDUS News Items
RDUS News Results
|Loading, please wait...|
RDUS News Highlights
- RDUS's 30 day story count now stands at 6.
- Over the past 17 days, the trend for RDUS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about RDUS are BEAT, DECK and ID.
Latest RDUS News From Around the Web
Below are the latest news stories about Radius Health Inc that investors may wish to consider to help them evaluate RDUS as an investment opportunity.
The following slide deck was published by Radius Health, Inc. in conjunction with their 2022 Q4 earnings call....
Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208 million in FY 2020, up 5%Net Loss reduced by ~36%: ($70) million FY 2021 vs ($109) million FY 2020Adjusted EBITDA (Non-GAAP) loss reduced by ~56%: ($24) million FY 2021 vs. ($54) million FY 2020FY 2022 financial objectives: $232 million TYMLOS Net RevenueIncorporate seasonality of Net Revenue: ~42% in 1H
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022
BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update. Conference Call Information:Domestic Dial-In Number: 1 (866) 323-7965International Dial-In Number: 1 (346) 406-0961Conference ID: 7696052Webcast Link: https://edge.me
We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Radius Health <
Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructureNon-Sales headcount reduced by approximately 20%Reductions focused on areas that supported abaloparatide clinical and regulatory activitiesCompany to provide Q4 & FY 2021 results and 2022 outlook during earnings on February 24 BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), has completed an adjustment of its business. The catalyst for the chang
Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.
The FDA has approved updates to Radius Health Inc''s (NASDAQ: RDUS ) Tymlos label, including removing the boxed warning